News & Updates

Show Multimedia Only

Implantable neurostimulator for Parkinson’s disease shows sustained benefits

30 Sep 2025 by

In the treatment of Parkinson’s disease (PD), the improvements observed following deep brain stimulation of the subthalamic nucleus using an implantable pulse generator system persisted over a 5-year period, according to long-term data from the INTREPID trial.

Implantable neurostimulator for Parkinson’s disease shows sustained benefits

30 Sep 2025

New HTN guidelines advocate for early Tx

30 Sep 2025 by

The new ACC/AHA* hypertension guidelines reinforce previous recommendations to lower blood pressure (BP) early and aggressively, with a greater emphasis on lifestyle interventions, the link between BP and cognitive function, and pregnancy.

New HTN guidelines advocate for early Tx

30 Sep 2025

Levodopa trial for poststroke recovery misses mark

29 Sep 2025 by

Incorporating levodopa into standardized rehabilitation therapy does not confer meaningful benefits in terms of motor function in patients recovering from stroke, as shown in the ESTREL trial.

Levodopa trial for poststroke recovery misses mark

29 Sep 2025

Semaglutide, dulaglutide help prevent cognitive decline in HF patients

28 Sep 2025 by

Treatment with semaglutide and dulaglutide results in a significantly lower risk of adverse cognitive decline in patients with heart failure (HF), as shown by the results of a retrospective cohort study using real-world data.

Semaglutide, dulaglutide help prevent cognitive decline in HF patients

28 Sep 2025

Shortened apixaban therapy ups bleeding in VTE patients

25 Sep 2025

Patients treated with shortened lead-in apixaban for venous thromboembolism (VTE) show increased bleeding events, and those with bleeding risk factors appear to gain no benefit from taking apixaban 10 mg twice daily, according to a study.

Shortened apixaban therapy ups bleeding in VTE patients

25 Sep 2025

Original New Drug Application Approvals by US FDA (16-31 August 2025)

24 Sep 2025

New drug applications approved by US FDA as of 16-31 August 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 August 2025)

24 Sep 2025

Chronic insomnia promotes faster mental decline, dementia

23 Sep 2025 by

People with chronic insomnia face an accelerated rate of cognitive decline and an increased risk of dementia, as shown in new research.

Chronic insomnia promotes faster mental decline, dementia

23 Sep 2025

Hypertensive disorders of pregnancy may impair childhood neurodevelopment

22 Sep 2025 by

Hypertensive disorders of pregnancy (HDPs) appear to increase the odds of adverse neurodevelopmental and cognitive outcomes, such as autism and attention-deficit/hyperactivity disorder (ADHD), in the offspring, suggest the results of a meta-analysis.

Hypertensive disorders of pregnancy may impair childhood neurodevelopment

22 Sep 2025

5-HTP daily boosts cognitive health in older Singaporeans

20 Sep 2025 by

Daily supplementation with 5-hydroxytryptophan (5-HTP) appears to confer cognitive benefits and reduce depression symptoms in older adults in Singapore, according to a study.

5-HTP daily boosts cognitive health in older Singaporeans

20 Sep 2025

Childhood loneliness may have enduring consequences on cognitive health

20 Sep 2025

Childhood loneliness appears to contribute to an increased risk of cognitive decline and dementia in middle and later adulthood, even in the absence of adult loneliness, according to a study.

Childhood loneliness may have enduring consequences on cognitive health

20 Sep 2025

News & Updates

Filter by Specialty:

Specialty:

Implantable neurostimulator for Parkinson’s disease shows sustained benefits

Implantable neurostimulator for Parkinson’s disease shows sustained benefits

New HTN guidelines advocate for early Tx

New HTN guidelines advocate for early Tx

Levodopa trial for poststroke recovery misses mark

Levodopa trial for poststroke recovery misses mark

Semaglutide, dulaglutide help prevent cognitive decline in HF patients

Semaglutide, dulaglutide help prevent cognitive decline in HF patients

Shortened apixaban therapy ups bleeding in VTE patients

Shortened apixaban therapy ups bleeding in VTE patients

Original New Drug Application Approvals by US FDA (16-31 August 2025)

Original New Drug Application Approvals by US FDA (16-31 August 2025)

Chronic insomnia promotes faster mental decline, dementia

Chronic insomnia promotes faster mental decline, dementia

Hypertensive disorders of pregnancy may impair childhood neurodevelopment

Hypertensive disorders of pregnancy may impair childhood neurodevelopment

5-HTP daily boosts cognitive health in older Singaporeans

5-HTP daily boosts cognitive health in older Singaporeans

Childhood loneliness may have enduring consequences on cognitive health

Childhood loneliness may have enduring consequences on cognitive health